Abstract
Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. Prevalence and incidence rates are rising with the advancing population age. A severe complication of untreated AF is thrombus formation in the left atrial appendage with consecutive peripheral thromboembolism. Thus, AF is a major contributor to thromboembolic events, especially in the elderly. Depending on the CHADS2 score for thromboembolic events that takes into account congestive heart failure, hypertension, age, diabetes mellitus and stroke as risk factors, oral anticoagulation therapy with vitamin K antagonists is currently the treatment of choice for the prevention of thromboembolism. However, due to drawbacks of current anticoagulation therapy new substances for oral therapy are currently evaluated in various clinical studies. This article provides an up to date overview of orally active compounds for the future treatment of AF. Emphasis lies on comparison of direct thrombin inhibitors with factor Xa inhibitors that are currently investigated in clinical phase III studies for the treatment of non-valvular AF. The direct thrombin inhibitor dabigatran will be compared with factor Xa inhibitors like rivaroxaban and apixaban. Other promising agents currently investigated in phase II trials such as direct factor Xa inhibitors DU-176b (edoxaban) and YM150, will also be discussed.
Keywords: Atrial fibrillation, anticoagulation, pathophysiology, pharmacology, stroke, thromboembolism, congestive heart failure, hypertension, diabetes mellitus, thrombin inhibitors, thrombin, factor Xa Inhibitors
Current Vascular Pharmacology
Title: Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Volume: 9 Issue: 3
Author(s): Oliver Wolfram, Matthias Hammwoehner, Felix Gramley and Andreas Goette
Affiliation:
Keywords: Atrial fibrillation, anticoagulation, pathophysiology, pharmacology, stroke, thromboembolism, congestive heart failure, hypertension, diabetes mellitus, thrombin inhibitors, thrombin, factor Xa Inhibitors
Abstract: Atrial fibrillation (AF) is the most common clinically relevant cardiac arrhythmia. Prevalence and incidence rates are rising with the advancing population age. A severe complication of untreated AF is thrombus formation in the left atrial appendage with consecutive peripheral thromboembolism. Thus, AF is a major contributor to thromboembolic events, especially in the elderly. Depending on the CHADS2 score for thromboembolic events that takes into account congestive heart failure, hypertension, age, diabetes mellitus and stroke as risk factors, oral anticoagulation therapy with vitamin K antagonists is currently the treatment of choice for the prevention of thromboembolism. However, due to drawbacks of current anticoagulation therapy new substances for oral therapy are currently evaluated in various clinical studies. This article provides an up to date overview of orally active compounds for the future treatment of AF. Emphasis lies on comparison of direct thrombin inhibitors with factor Xa inhibitors that are currently investigated in clinical phase III studies for the treatment of non-valvular AF. The direct thrombin inhibitor dabigatran will be compared with factor Xa inhibitors like rivaroxaban and apixaban. Other promising agents currently investigated in phase II trials such as direct factor Xa inhibitors DU-176b (edoxaban) and YM150, will also be discussed.
Export Options
About this article
Cite this article as:
Wolfram Oliver, Hammwoehner Matthias, Gramley Felix and Goette Andreas, Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?, Current Vascular Pharmacology 2011; 9 (3) . https://dx.doi.org/10.2174/157016111795495512
DOI https://dx.doi.org/10.2174/157016111795495512 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calpains: Potential Targets for Alternative Chemotherapeutic Intervention Against Human Pathogenic Trypanosomatids
Current Medicinal Chemistry Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Why Should Rheumatologists Consider Vitamin D Supplementation for their Patients?
Current Rheumatology Reviews Severe Neutropenia in a Renal Transplant Patient Suggesting an Interaction Between Mycophenolate and Fenofibrate
Current Drug Safety Colchicine in Renal Diseases: Present and Future
Current Pharmaceutical Design Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting
Current Gene Therapy Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Marine Peptides for Preventing Metabolic Syndrome
Current Protein & Peptide Science Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Eosinophilopoiesis at the Cross-Roads of Research on Development, Immunity and Drug Discovery
Current Medicinal Chemistry Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews Current Hydrogel Solutions for Repairing and Regeneration of Complex Tissues
Current Medicinal Chemistry